Display options
Cite
Philips A, Radhakrishnan V, Ganesan P, et al. Efficacy of Single Dose Rasburicase (1.5 mg) for Prophylaxis and Management of Laboratory Tumor Lysis Syndrome. Indian J Hematol Blood Transfus. 2018;34(4):618-622doi: 10.1007/s12288-018-0938-9.
Philips, A., Radhakrishnan, V., Ganesan, P., Ganesan, T. S., Ramamurthy, J., Dhanushkodi, M., & Sagar, T. G. (2018). Efficacy of Single Dose Rasburicase (1.5 mg) for Prophylaxis and Management of Laboratory Tumor Lysis Syndrome. Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion, 34(4), 618-622. https://doi.org/10.1007/s12288-018-0938-9
Philips, Ashwin, et al. "Efficacy of Single Dose Rasburicase (1.5 mg) for Prophylaxis and Management of Laboratory Tumor Lysis Syndrome." Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion vol. 34,4 (2018): 618-622. doi: https://doi.org/10.1007/s12288-018-0938-9
Philips A, Radhakrishnan V, Ganesan P, Ganesan TS, Ramamurthy J, Dhanushkodi M, Sagar TG. Efficacy of Single Dose Rasburicase (1.5 mg) for Prophylaxis and Management of Laboratory Tumor Lysis Syndrome. Indian J Hematol Blood Transfus. 2018 Oct;34(4):618-622. doi: 10.1007/s12288-018-0938-9. Epub 2018 Mar 03. PMID: 30369730; PMCID: PMC6186245.
Copy Download .nbib Format: NLM
Share it on

Indian J Hematol Blood Transfus. 2018 Oct;34(4):618-622. doi: 10.1007/s12288-018-0938-9. Epub 2018 Mar 03.

Efficacy of Single Dose Rasburicase (1.5 mg) for Prophylaxis and Management of Laboratory Tumor Lysis Syndrome.

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion

Ashwin Philips, Venkatraman Radhakrishnan, Prasanth Ganesan, T S Ganesan, Jaikumar Ramamurthy, Manikandan Dhanushkodi, T G Sagar

Affiliations

  1. Department of Medical Oncology, Cancer Institute (WIA), Adyar, Chennai, Tamilnadu India.

PMID: 30369730 PMCID: PMC6186245 DOI: 10.1007/s12288-018-0938-9

Abstract

Rasburicase is a recombinant urate oxidase enzyme approved for use in tumor lysis syndrome (TLS) and it acts by reducing serum uric acid levels. Using rasburicase at the recommended dose of 0.2 mg/kg/day for 5 days is expensive and it is not known whether this extended schedule is clinically beneficial compared to a single fixed dose of 1.5 mg. The aim of the present study was to evaluate the efficacy of single dose rasburicase 1.5 mg in prevention and management of TLS. Rasburicase is available as single use 1.5 mg vial. At our institution a single dose of rasburicase 1.5 mg irrespective of bodyweight has been used in adults and in children a dose of 0.15 mg/kg (maximum 1.5 mg) has been used since 2012 for prevention and management of TLS and subsequent doses are given based on biochemical response and clinical condition. We retrospectively analysed the case records of patients who had received rasburicase from January 2012 to January 2017. The study included 186 patients with hematological malignancies who received rasburicase. Children accounted for 56.4% (n = 105) patients and males comprised 73% (n = 135). Rasburicase was used prophylactically in 59 (31.7%) patients, for laboratory TLS in 76 patients (40.8%) and for clinical TLS in 51 (27.4%) patients. Single fixed dose rasburicase prevented laboratory/clinical TLS in 87% of the prophylactic group and prevented clinical TLS in 72% of the laboratory TLS group. None of the patients in prophylactic and laboratory TLS group developed clinical TLS. However, majority of the patients with clinical TLS required more than one dose rasburicase. Single dose of 1.5 mg (1 vial) rasburicase is efficient in preventing and managing laboratory TLS and is economically viable in resource constrained settings.

Keywords: Rasburicase; Renal failure; Tumor lysis syndrome

Conflict of interest statement

The authors declare that they have no conflict of interest.All procedures performed in the study were in accordance with the ethical standards of the institutional research committee and with the 1964

References

  1. Pharmacotherapy. 2013 Mar;33(3):295-303 - PubMed
  2. Ann Pharmacother. 2010 Oct;44(10):1529-37 - PubMed
  3. Br J Haematol. 2004 Oct;127(1):3-11 - PubMed
  4. Br J Clin Pharmacol. 2013 Feb;75(2):550-3 - PubMed
  5. Indian J Nephrol. 2015 Mar-Apr;25(2):91-4 - PubMed
  6. N Engl J Med. 2011 May 12;364(19):1844-54 - PubMed
  7. J Oncol Pharm Pract. 2015 Apr;21(2):111-7 - PubMed
  8. Blood. 2001 May 15;97(10):2998-3003 - PubMed
  9. Indian J Pediatr. 2015 May;82(5):458-61 - PubMed
  10. Ann Oncol. 2012 Jun;23(6):1640-5 - PubMed
  11. J Oncol Pharm Pract. 2017 Jul;23(5):333-337 - PubMed
  12. J Clin Pharm Ther. 2013 Aug;38(4):301-8 - PubMed
  13. Bone Marrow Transplant. 2011 Jun;46(6):800-5 - PubMed
  14. J Clin Oncol. 2010 Sep 20;28(27):4207-13 - PubMed
  15. Asia Pac J Clin Oncol. 2011 Dec;7(4):351-6 - PubMed

Publication Types